Sunday, December 4, 2016

Systematic review of the cost-effectiveness of implementing guidelines on low back pain management in primary care

Abstract

Objective The primary aim is to identify, summarise and quality assess the available literature on the cost-effectiveness of implementing low back pain guidelines in primary care. The secondary aim is to assess the transferability of the results to determine whether the identified studies can be included in a comparison with a Danish implementation study to establish which strategy procures most value for money.
Design Systematic review.
Data sources The search was conducted in Embase, PubMed, Cochrane Library, NHS Economic Evaluation Database, Scopus, CINAHL and EconLit. No restrictions were made concerning language, year of publication or publication type. The bibliographies of the included studies were searched for any studies not captured in the literature search.
Eligibility criteria for selecting studies To be included, a study must be: (1) based on a randomised controlled trial comparing implementation strategies, (2) the guideline must concern treatment of low back pain in primary care and (3) the economic evaluation should contain primary data on cost and cost-effectiveness.
Results The title and abstract were assessed for 308 studies; of these, three studies were found eligible for inclusion. The Consensus Health Economic Criteria (CHEC) list showed that the 3 studies were of moderate methodological quality while application of Welte's model showed that cost results from two studies could, with adjustments, be transferred to a Danish setting. It was questionable whether the associated effects could be transferred.
Conclusions Despite the resemblance of the implementation strategies, the 3 studies report conflicting results on cost-effectiveness. This review showed that transferring the results from the identified studies is not straightforward and underlines the importance of transparent reporting. Future research should focus on transferability of effects, for example, development of a supplement to Welte's model.
Integrity Life Sciences delivers a multitude of orthotic treatment options to address one of the most costly systemic ailments in the world, chronic low back and neck pain. Our advanced solution begins with the Integrity Spinal Care System (ISCS) ™ and its proprietary iELCiPS Technology™. The ISCS non-surgical spinal decompression modality systems are engineered to provide pain relief for compressive and degenerative conditions of the spine. Specifically, conditions that may be treated include: neck pain and back pain associated with herniated discs, protruding discs, degenerative disc disease, posterior facet syndrome, and sciatica. It achieves these effects through decompression of intervertebral discs, that is, unloading due to distraction and positioning.
As a compliment to the ISCS, Integrity offers the very effective Integrity Gel Support Brace™. Our advanced lumbar support brace is a fitting compliment to non-surgical spinal decompression therapy and was designed as an adjunct therapy for those suffering from back pain due to disc related conditions. The Integrity Gel Support Brace may be used with or without Integrity's non-surgical spinal decompression systems and is an excellent treatment option for the patient to use at home.
In addition, Integrity Life Sciences has been exclusively granted the use of all of the technology, products, US Patent and Trademark Offices assignments, logos and other forms of intellectual property that were created by Axiom Worldwide, INC under the leadership of Jim Gibson from Tampa, Florida. The agreement specifically includes the flagship product DRX9000™, its family of products, and all of its derivatives such as the DRX9000C. Integrity offers support for these products, which includes: sales, maintenance services, and repairs. Only Integrity Life Sciences is Registered with the US FDA as a Factory Authorized - Contract Manufacturer - for Axiom Worldwide and the DRX9000 True Non-Surgical Spinal Decompression Systems™
James Gibson, President of Integrity Life Sciences and Axiom Worldwide states "Our partners, in over 50 countries and territories, have the unique opportunity to present a cutting edge medical device, utilizing a clinically validated protocol that restores a patient’s quality of life non-surgically and without pharmaceutical or invasive intervention". With a body of published clinical research from around the world will support and strengthen your sales presentation; members of our medical advisory board herald from prestigious institutions such as Johns-Hopkins and The Mayo Clinic just to name a few. In addition, partners will have confidence in a quality product that adheres to the stringent standards mandated by FDA, CE, and ISO. Sales, marketing, and technical training is offered in prestigious locations in Europe, Asia, the Middle East and throughout the United States. 
Integrity Life Sciences, LLC and Axiom Worldwide, INC are privately held companies with global partners and shareholders USA based company with international partners located across the globe with a mission of "Restoring Integrity to the Spine™". 

For additional information please visit: www.IntegrityLifeSciences.com

Elements as Published in: BMJ British Medical Journal

1 comment:

  1. Nice reading, I love your content. This is really a fantastic and informative post. Keep it up and if you are looking for Clifton Pain Management then consult with our best doctors, they will help you.

    ReplyDelete